Summary:
This study is phase 3 multicenter, randomized, double blind, parallel group, placebo controlled study of two fixed doses 0.1 and 0.4 mg of TAK-375-SL tablets in subject with acute depressive episode associated with Bipolar 1 Disorder.
Qualified Participants Must:
• Be between 18 to 75 years of age
•
Currently be taking medication for Bipolar Disorder
Qualified Participants May Receive:
Free medical evaluation, free study medication and compensation for time and travel.